-
1 Comment
Hansoh Pharmaceutical Group Company Limited is currently in a long term downtrend where the price is trading 11.0% below its 200 day moving average.
From a valuation standpoint, the stock is 79.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.7.
Hansoh Pharmaceutical Group Company Limited's total revenue rose by 15.4% to $5B since the same quarter in the previous year.
Its net income has increased by 6.9% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 104.3% to $681M since the same quarter in the previous year.
Based on the above factors, Hansoh Pharmaceutical Group Company Limited gets an overall score of 4/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| Sector | Healthcare |
| ISIN | KYG549581067 |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | 28.72 |
|---|---|
| Target Price | 26.4864 |
| Dividend Yield | 1.2% |
| Market Cap | 133B |
| Beta | 0.66 |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 3692.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
